Mechanism of action ULTOMIRIS® was shown to achieve immediate, complete and sustained C5 inhibition over 26 weeks and extension period treatment.1-3
aHUS is a form of thrombotic microangiopathy (TMA) caused by overactivation of the terminal complement system. The overactivation of terminal complement system triggers a destructive cycle of endothelial damage and dysfunction which leads to thrombosis, destruction of erythrocytes and organ damage and dysfunction.4-6
With its extended half-life,2,3 ULTOMIRIS® requires once every 4 or 8 week infusions for your patients, while sustaining terminal complement inhibition.
Adverse Event Reporting

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com/
ULTOMIRIS® EU Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: December 2024. Rondeau E, et al. Kidney Int. 2020;97(6):1287-1296. Sheridan D, et al. PLoS One. 2018;13(4): e0195909. Laurence J, et al. Clin Adv Hematol Oncol. 2016;14(11):2–15. Azoulay E, et al. Chest. 2017;152(2):424–434. Yerigeri K, et al. J Multidiscip Healthc 2023;16:2233–49. Ariceta G, et al. Kidney Int. 2021;100(1):225–237.